A phase 1/2 trial of OBI-902 in advanced solid tumours, run by OBI Pharma, Inc, now recruiting.
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07124117 by OBI Pharma, Inc, with 147 participants planned, started 2025-08-04 and due to reach its primary completion in 2029-02-08. Interventions recorded: OBI-902.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.